Delivery Order SPE2DB22D2206-SPE2DB25FJC35
- Not listed
- The U.S. Department of Defense Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $18,377.82 for Cathflo Activase 2 mg vials, with a completion date of August 13, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award carries no...
- The Defense Logistics Agency awarded a $2,262.40 firm fixed price delivery order to AmerisourceBergen Drug Corp for Cathflo Activase 2 mg vials, with an ultimate completion date of August 19, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,262.40 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials, a thrombolytic medication used to restore function to central venous catheters. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and was competitively awarded without set-aside restrictions. AmerisourceBergen's Corporate Office division, headquartered in Conshohocken, Pennsylvania,...
- This delivery order, valued at $4,524.80, was awarded to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Cathflo Activase 2 mg vials. The contract is a firm fixed price, non-set-aside award funded by the Defense Logistics Agency (DLA) and is scheduled for completion by July 21, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a discrete purchase under the company's broader pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $16,297.10 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials, a thrombolytic medication used in medical applications. The contract was executed as a firm fixed-price delivery order on July 31, 2025, with an ultimate completion date of August 1, 2025, and does not include a set-aside designation. Performance will be fulfilled at the vendor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,374.60 for Cathflo Activase 2 mg vials, effective July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed price delivery order was awarded without a set-aside designation through open competition and will be performed at the contractor's Conshohocken, Pennsylvania facility. Cathflo Activase is a thrombolytic agent used in medical settings to restore function to occluded...
- The Defense Logistics Agency awarded a Delivery Order (Contract 4569100232) valued at $11,600 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials, a thrombolytic medication used to restore function to occluded central venous catheters in medical settings. This firm fixed-price, competitively awarded delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the contractor's corporate office location in...
- This delivery order, issued on August 7, 2025, awards AmerisourceBergen Drug Corp $1,696.80 for the supply of Cathflo Activase 2 mg vials under a firm fixed price contract. The award is funded by the Defense Logistics Agency, a defense-focused component of the Department of Defense responsible for supplying medical and pharmaceutical commodities to military and veteran healthcare systems. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The contract, valued at $8,126.50, is for the provision of 2 mg vials of the medication Cathflo Activase. This delivery order does not have a set-aside designation. Amerisourcebergen Drug Corp, through its Corporate Office division in Conshohocken, Pennsylvania, is the prime...
- The Defense Logistics Agency awarded a delivery order valued at $5,429.76 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials. This firm fixed-price contract, with an ultimate completion date of August 19, 2025, represents a pediatric thrombolytic medication used in medical settings to restore blood flow in occluded central venous catheters. The award was made on a competitive basis with no set-aside designation, and performance will take place at AmerisourceBergen's...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJC35Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,949.43 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials under a firm fixed-price contract. This non-set-aside award, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a routine pharmaceutical procurement from the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as the comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains, from specialty medications to generic drugs, vaccines, and medical devices. This delivery order for Cathflo Activase continues the company's role as a key supplier within the DLA's pharmaceutical supply chain, supporting military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.9k | 7/28/25 |